quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 10, 2025

RadNet raises 2025 revenue guidance as advanced imaging volumes and digital health drive growth

View original at seekingalpha.com
RadNet raises 2025 revenue guidance as advanced imaging volumes and digital health drive growth Earnings Call Insights: RadNet, Inc. (RDNT) Q3 2025 MANAGEMENT VIEW * CEO Howard Berger opened by stating, "I am very pleased with the performance in the third quarter…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • RadNet needs more sales personnel post-iCAD acquisition, and margin expansion will increasingly be driven by digital health tools.

    80% confidence
  • Aggregate MRI volume increased 14.8%, CT volume increased 9.4%, and PET/CT volume increased 21.1% from Q3 2024.

    80% confidence
  • Exposure to Medicaid and health insurance exchanges is minimal, reducing risk from policy changes.

    80% confidence
  • RadNet increased imaging center revenue guidance by $50 million at the low end and $30 million at the high end, and increased adjusted EBITDA guidance by $5 million at both ends.

    80% confidence
  • RadNet operates 407 centers as of September 30, 2025, with one new center opened during Q3 and 4.9% total same-center procedure volume growth.

    80% confidence
  • AI revenue within Digital Health, inclusive of iCAD revenue from ProFound AI and Deep Health solutions, increased 112% from Q3 2024.

    80% confidence
  • See-Mode's thyroid ultrasound technology achieved a 30% reduction in scan time across 240+ centers.

    80% confidence
  • TechLive rollout should be substantially complete by the end of 2025, and has reduced exam closure hours by about 42% relative to last year.

    80% confidence
  • Advanced imaging volumes increased 13.0% on an aggregate basis and 9.9% on a same-center basis, driven by equipment upgrades, AI-driven scheduling, capacity expansion, and shift from hospital to ambulatory imaging.

    80% confidence
  • 2026 Medicare reimbursement changes will benefit RadNet with approximately $4-5 million revenue uplift on roughly $2 billion of revenue.

    80% confidence
  • iCAD contributed approximately $3.9 million in revenue during Q3 2025.

    80% confidence
  • EBCD payer adoption discussions are progressing positively with increasing traction, though large payers move slowly.

    80% confidence
  • Total company revenue increased 13.4% and adjusted EBITDA increased 15.2% relative to Q3 2024, resulting in a 26 basis point improvement in adjusted EBITDA margins.

    80% confidence
  • Adjusted EBITDA margins increased by 26 basis points from 16% to 16.2% year-over-year.

    80% confidence
  • EBCD AI revenue rose 28.7% year-over-year.

    80% confidence
  • Digital Health revenue increased 51.6% from Q3 2024, partially due to iCAD's revenue contribution since July 17 acquisition.

    80% confidence
  • DSOs (Days Sales Outstanding) reduced to 31.9 days, the lowest historical level for RadNet.

    80% confidence
  • PET/CT growth is driven by PSMA and amyloid brain studies, which now make up 20% of PET/CT volume.

    80% confidence
  • Labor markets for radiology technologists remain challenging but have stabilized, and RadNet is seeing increasing inbound calls from health systems for partnership opportunities.

    80% confidence
  • Cash balance as of September 30, 2025 was $804.7 million with net debt to adjusted EBITDA ratio of approximately 1.0.

    80% confidence
  • Virtual radiology is an inevitability, and DeepHealth serves as a platform to bundle and integrate multiple AI modules for both internal and external customers.

    80% confidence
  • Q3 2025 revenue and adjusted EBITDA were both quarterly records and exceeded internal budgets set at the beginning of 2025.

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
RadNet raises 2025 revenue guidance as advanced imaging volumes and digital health drive growth — Source | Via News | pt.VIA.NEWS